Market Closed -
Nasdaq
21:00:00 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
42.39
USD
|
+6.59%
|
|
+13.80%
|
+601.82%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
353.1
|
105
|
77.1
|
13.84
|
26.72
|
445.4
|
-
|
-
|
Enterprise Value (EV)
1 |
353.1
|
105
|
77.1
|
13.84
|
26.72
|
445.4
|
445.4
|
445.4
|
P/E ratio
|
-4.88
x
|
-0.88
x
|
-1.66
x
|
-0.33
x
|
-0.59
x
|
-7.23
x
|
-7.3
x
|
-3.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.77
x
|
26.7
x
|
87.4
x
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
9.77
x
|
26.7
x
|
87.4
x
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7,286,222
x
|
-1,048,682
x
|
-1,598,427
x
|
-368,592
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,156
|
2,801
|
4,174
|
4,176
|
4,424
|
10,507
|
-
|
-
|
Reference price
2 |
163.8
|
37.50
|
18.47
|
3.315
|
6.040
|
42.39
|
42.39
|
42.39
|
Announcement Date
|
12/03/20
|
15/03/21
|
08/03/22
|
07/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
36.14
|
3.937
|
0.8817
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-77.1
|
-122.8
|
-55.99
|
-39.84
|
-45.08
|
-51.73
|
-71.21
|
-103.7
|
Operating Margin
|
-213.33%
|
-3,119.2%
|
-6,350.05%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-71.45
|
-111.3
|
-45.64
|
-42.35
|
-44.6
|
-50.86
|
-69.49
|
-102.1
|
Net income
1 |
-71.45
|
-111.3
|
-45.64
|
-42.35
|
-44.6
|
-49.51
|
-69.49
|
-102.1
|
Net margin
|
-197.69%
|
-2,826.08%
|
-5,176.35%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-33.60
|
-42.60
|
-11.10
|
-10.15
|
-10.31
|
-5.860
|
-5.805
|
-10.76
|
Free Cash Flow
|
-48.46
|
-100.2
|
-48.24
|
-37.56
|
-
|
-
|
-
|
-
|
FCF margin
|
-134.09%
|
-2,544.18%
|
-5,470.95%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
15/03/21
|
08/03/22
|
07/03/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.0973
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.88
|
-9.998
|
-8.517
|
-12.34
|
-8.181
|
-10.8
|
-17.3
|
-8.189
|
-9.488
|
-10.1
|
-9.623
|
-11.67
|
-14.31
|
-16.18
|
-
|
Operating Margin
|
-14,257.51%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.176
|
-10.26
|
-9.437
|
-13.25
|
-8.782
|
-10.88
|
-17.74
|
-8.784
|
-10.05
|
-8.021
|
-6.899
|
-11.84
|
-14.51
|
-16.32
|
-
|
Net income
1 |
-2.176
|
-10.26
|
-9.437
|
-13.25
|
-8.782
|
-10.88
|
-17.74
|
-8.784
|
-10.05
|
-8.021
|
-6.899
|
-11.84
|
-14.51
|
-16.32
|
-
|
Net margin
|
-2,236.08%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-2.400
|
-2.400
|
-3.300
|
-2.100
|
-2.610
|
-4.240
|
-2.050
|
-2.270
|
-1.810
|
-0.8300
|
-1.405
|
-1.710
|
-1.895
|
-1.240
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
08/03/22
|
10/05/22
|
09/08/22
|
08/11/22
|
07/03/23
|
09/05/23
|
08/08/23
|
07/11/23
|
12/03/24
|
07/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-48.5
|
-100
|
-48.2
|
-37.6
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
2.74
|
0.48
|
0.05
|
0.01
|
-
|
-
|
-
|
-
|
Capex / Sales
|
7.59%
|
12.31%
|
6.14%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
15/03/21
|
08/03/22
|
07/03/23
|
12/03/24
|
-
|
-
|
-
|
Last Close Price
42.39
USD Average target price
68
USD Spread / Average Target +60.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +601.82% | 418M | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|